Welcome to our dedicated page for Mosaic Immunoengineering SEC filings (Ticker: CPMV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mosaic Immunoengineering's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mosaic Immunoengineering's regulatory disclosures and financial reporting.
Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company aiming to build an immuno-oncology pipeline but currently has no active product candidates. The company focuses on licensing or acquiring cancer immunotherapies rather than advancing an existing in-house portfolio.
As of December 31, 2025, Mosaic reported cash of $3,622, current liabilities of $6,030,055 and an accumulated deficit of $9,526,166. Management states there is substantial doubt about its ability to continue as a going concern because existing resources are insufficient to fund current obligations or planned operations for the next twelve months.
Mosaic entered a binding term sheet with Oncotelic Therapeutics in April 2024 to acquire clinical-stage necroptosis cancer therapies and AI technology in exchange for equity valued at $15.0 million, plus up to an additional $15.0 million in milestone shares, but the term sheet expired on June 30, 2025 and no definitive agreement has been finalized. The company is highly dependent on raising additional capital, including convertible notes, and warns that failure to secure funding could force it to cease operations.
Mosaic ImmunoEngineering, Inc. notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 because additional time, resources and effort are required to complete financial close and reporting procedures.
The company states it expects to file the Form 10-K no later than the fifteenth calendar day following the prescribed due date.
Mosaic ImmunoEngineering, Inc. reported a Q3 2025 net loss of $165,361, improving from a $186,730 loss a year earlier, as both research and development and general and administrative costs declined. For the first nine months of 2025, the company recorded a net loss of $518,709, versus $768,939 in the prior-year period, reflecting lower payroll and operating expenses.
Cash and cash equivalents were only $31,761 as of September 30, 2025, against total liabilities of $7,362,181 and a stockholders’ deficit of $7,306,883, and management states there is substantial doubt about the company’s ability to continue as a going concern without new capital. Mosaic remains a development-stage oncology-focused biotech, has not generated revenue, and is relying on future financings while its previous $15.0 million asset acquisition term sheet with Oncotelic has expired. As of November 19, 2025, 7,242,137 common shares were outstanding.
Mosaic ImmunoEngineering filed a Form 12b-25, notifying a late filing of its Quarterly Report on Form 10-Q. The company cites the need for additional time, resources, and effort to complete financial reporting and close procedures. It expects to file the Form 10-Q as soon as possible, and on or before the fifth calendar day following the prescribed due date.